Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Preoperative Monitoring and Surgical Options for HER2+ Patients

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 29th 2024

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

June 28th 2024

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer

June 28th 2024

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

June 28th 2024

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.

Dr O'Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancer

June 27th 2024

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance

June 26th 2024

Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

June 25th 2024

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

First-Line Toripalimab Plus Chemo Wins Approval in China for Advanced TNBC

June 25th 2024

China’s NMPA approved toripalimab plus nab-paclitaxel for the first-line treatment of recurrent or metastatic triple-negative breast cancer.

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Evolution of Testing Strategies for ESR1

June 25th 2024

The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.

Prevalence and Testing Strategies for ESR1

June 25th 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.